Ask AI
Bispecific Antibodies in MM

CE

APP Perspectives: Managing Toxicities With Bispecific Antibodies in Multiple Myeloma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 07, 2025

Expiration: May 06, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

You are treating a patient with teclistamab who completed step-up dosing and is on cycle 6 of standard dosing. The patient presents with a new fever and general fatigue. What potential cause do you suspect?

2.

You are reviewing the unique AE profiles of BCMA- and GPRC5D-targeted bispecific antibody therapies with a patient with relapsed/refractory (R/R) multiple myeloma (MM) and their caregiver. Which of the following AEs is more commonly observed with GPRC5D-targeted therapy compared with BCMA-targeted therapy in MM?